BioSpace News Archive

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is pleased to announce it is hiring four new biotechnologists to re-establish the Company’s production of ACP-01 in Montreal.

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies,

ONWARD Medical N.V. announced two key appointments to its leadership team to drive the Company’s clinical research and commercial activities.

DiscGenics, Inc. today announced positive two-year clinical data from its first-in-human clinical study of IDCT (rebonuputemcel), an allogeneic discogenic progenitor cell therapy for lumbar degenerative disc disease (DDD).

Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs, will be presenting at the Emerging Growth Conference on January 25, 2023.

Avadel Pharmaceuticals plc, a company focused on transforming medicines to transform lives, announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to three new employees to purchase an aggregate of 40,500 ordinary shares under Avadel’s 2021 Inducement Plan.

Fabrinet announced it will release its second quarter fiscal year 2023 financial results for the period ended December 30, 2022 after market close on Monday, February 6, 2023.

Asia Green Biotechnology Corp. (“Asia Green” or the “Company”) (CSE:ASIA) announces that it has obtained additional financing and completed the next payment to facilitate its continuing scientific trials activities with respect to treatments for migraine and related health issues being developed by Pathway RX Inc. and Swysh Inc., Asia Green’s research and development partners.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that Astellas and Sandoz AG (“Sandoz”) have entered into an Asset Purchase Agreement, under which Astellas will transfer the world wide product rights for antifungal agent MYCAMINE® (micafungin sodium/product name in Japan: FUNGUARD®).

RespireRx Pharmaceuticals Inc. is pleased to announce that the Company and the Board of Trustees of University of Illinois, a body corporate and politic of the State of Illinois, have agreed to a second amendment to their Exclusive License Agreement.